Crystalys Therapeutics

📍 San Diego, United States🗓 Founded 2025👥 16 employees💰 Last funded Feb 2026
Biotechnology Research🌐 crystalystx.com
Website LinkedIn
Crystalys is a clinical-stage biopharmaceutical company transforming the treatment of gout. Co-founded by Novo Holdings and Catalys Pacific, Crystalys brings together a world-class team with deep expertise in gout drug development, dedicated to delivering more effective options for people living with gout. Dotinurad, the company’s lead candidate and next-generation URAT1 inhibitor with best-in-class potential for safety and efficacy, is being advanced into global Phase 3 trials as a second-line therapy for gout, supported by extensive clinical data from approvals in multiple Asian markets.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2025
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Crystalys Therapeutics?
Crystalys Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Crystalys Therapeutics last raise funding?
The most recent investment in Crystalys Therapeutics recorded on gritt.io was in February 2026.
When was Crystalys Therapeutics founded?
Crystalys Therapeutics was founded in 2025.
What industry is Crystalys Therapeutics in?
Crystalys Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Crystalys Therapeutics based?
Crystalys Therapeutics is headquartered in San Diego, United States.